echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Yangzijiang Pharmaceutical, the number one in China's pharmaceutical industry, was fined 764 million heavily for monopoly

    Yangzijiang Pharmaceutical, the number one in China's pharmaceutical industry, was fined 764 million heavily for monopoly

    • Last Update: 2021-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Reporter | Yuan Yiming

    Edit | Xie Xin

    The State Administration for Market Regulation imposed administrative penalties on Yangzijiang Pharmaceutical Group Co.
    , Ltd.
    (hereinafter referred to as "Yangzijiang Pharmaceutical") for implementing a monopoly agreement on April 15, with a total fine of 764 million yuan
    .

    This is also the latest monopoly penalty imposed by the State Administration of Market Supervision on the pharmaceutical industry.
    Tianyao shares were also fined 44.
    02 million yuan for monopoly this month
    .

    However, compared with Tianyao, Yangtze River Pharmaceutical's volume and industry status are much larger in the pharmaceutical industry.
    In fact, Yangtze River Pharmaceutical has never been listed, but it is comparable to a "Big Mac" in China.
    The existence of >
    .


    According to the "2019 China Pharmaceutical Industry Top 100 List" released by the China Pharmaceutical Industry Information Center, Yangzijiang Pharmaceutical ranked first in the China Pharmaceutical Industry Top 100 list that year, and has ranked first for 6 consecutive years


    According to monopoly agreements penalty decision, since the way from 2015 to 2019, the Yangtze River Pharmaceutical and trading counterpart by signing a cooperation agreement, the price adjustment issued a letter, verbal notification to reach a fixed and limited price
    .


    There are more than 300 types of drugs involved.


    On December 22, 2020, after the "Administrative Punishment Notice" was delivered for the first time, Yangzijiang Pharmaceutical filed an application for a hearing
    .


    At the hearing on January 8, 2021, Yangzijiang Pharmaceutical stated that it had not implemented a monopoly agreement


    However, the State Administration of Market Supervision believes that Yangzijiang Pharmaceutical’s claims are “not valid” because: there is evidence that Yangzijiang Pharmaceutical has set various penalties for not implementing fixed and limited price policies, such as deductions, for each transaction partner in all aspects of drug sales.
    bonuses, stop reimbursements, stock and so on
    .


    At the same time, there is evidence that Yangtze River Pharmaceutical has imposed punitive measures on certain dealers who did not comply with fixed and limited price requirements, such as verbal warnings and threats, or even suspension of supply


    The above two points dismissed all statements made by Yangzijiang Pharmaceutical
    .


    The General Administration of Market Supervision also added that: Yangtze River Pharmaceutical's monopoly agreement has been effectively implemented, indicating that the establishment of penalties has sufficient deterrence, and there is no need to ensure implementation through actual implementation


    The State Administration for Market Regulation also revealed that the State Administration for Market Regulation had organized members of the Expert Advisory Group of the State Council’s Anti-Monopoly Committee to jointly convene an expert discussion meeting on this case
    .


    Participants agreed that the establishment of punitive measures is to better protect the implementation of the monopoly agreement


    The administrative penalty document also disclosed in the penalty reason: Yangtze River Pharmaceutical's illegal activities lasted for a long time and covered a wider area; it did not cooperate in the early stage of the investigation and delayed the inspection progress, but actively cooperated with the investigation in the later stage of the investigation to promote the progress of the investigation
    .

    Therefore, the State Administration of Market Supervision finally decided: to fine Yangzijiang Pharmaceutical in accordance with 3% of its 2018 sales
    .


    According to the "Special Audit Report of Jiangsu Jingwei Certified Public Accountants Co.


    It is worth mentioning that Yangtze River Pharmaceutical also sued the court for suspected monopoly of APIs by four companies including Guangzhou Hairui Pharmaceutical, Hefei Medical Industry and Pharmaceutical, Hefei Enruit Pharmaceutical, and Nanjing Haichen Pharmaceutical
    .


    In April 2020, the first instance of the case ended, and Yangzijiang Pharmaceutical was awarded nearly 70 million in compensation


    And a year later, Yangtze River Pharmaceutical lost more than ten times the money it had earned by suing others for its monopoly because of its own monopoly
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.